Monopar Therapeutics Q4 GAAP EPS $(0.12) Beats $(0.15) Estimate
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics (NASDAQ:MNPR) reported a Q4 GAAP EPS loss of $(0.12), surpassing the analyst consensus estimate of $(0.15) by 20%. This represents a 45.45% improvement over the $(0.22) per share loss from the same quarter last year.
March 28, 2024 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics reported a smaller than expected Q4 loss per share of $(0.12), beating estimates and showing significant improvement over last year.
Beating earnings estimates typically leads to positive investor sentiment and can result in a short-term increase in stock price. The significant improvement over the previous year's losses further strengthens the case for a positive outlook on MNPR's stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100